[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Wagner et al., 2012 - Google Patents

Identification and characterization of small molecule inhibitors of a plant homeodomain finger

Wagner et al., 2012

View PDF
Document ID
7659035874024619922
Author
Wagner E
Nath N
Flemming R
Feltenberger J
Denu J
Publication year
Publication venue
Biochemistry

External Links

Snippet

A number of histone-binding domains are implicated in cancer through improper binding of chromatin. In a clinically reported case of acute myeloid leukemia (AML), a genetic fusion protein between nucleoporin 98 and the third plant homeodomain (PHD) finger of JARID1A …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Wagner et al. Identification and characterization of small molecule inhibitors of a plant homeodomain finger
Bai et al. Rationalizing PROTAC-mediated ternary complex formation using Rosetta
Lu et al. Allosteric methods and their applications: facilitating the discovery of allosteric drugs and the investigation of allosteric mechanisms
Bemis et al. Unraveling the role of linker design in proteolysis targeting chimeras: Miniperspective
Cromm et al. Addressing kinase-independent functions of Fak via PROTAC-mediated degradation
Drummond et al. In silico modeling of PROTAC-mediated ternary complexes: validation and application
Johansson et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development
Gu et al. Surf the post-translational modification network of p53 regulation
Herold et al. Small-molecule ligands of methyl-lysine binding proteins
Foulkes et al. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells
Kimura et al. Deciphering cryptic binding sites on proteins by mixed-solvent molecular dynamics
Immormino et al. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors
Watts et al. Designing dual inhibitors of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) by tuning kinase selectivity
Leggans et al. A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20′ urea derivatives
Miller et al. Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger
Tashiro et al. Discovery and optimization of inhibitors of the Parkinson’s disease associated protein DJ-1
Davidovich et al. Discovery of novel isatin-based p53 inducers
Lee et al. Proximity-directed labeling reveals a new rapamycin-induced heterodimer of FKBP25 and FRB in live cells
Boulton et al. Mechanism of selective enzyme inhibition through uncompetitive regulation of an allosteric agonist
Jansson et al. DXR inhibition by potent mono-and disubstituted fosmidomycin analogues
Ignatov et al. High accuracy prediction of PROTAC complex structures
Ma et al. Synthesis and anti‐HIV activity of Aryl‐2‐[(4‐cyanophenyl) amino]‐4‐pyrimidinone hydrazones as potent non‐nucleoside reverse transcriptase inhibitors
Paulussen et al. Peptide‐based covalent inhibitors of protein–protein interactions
Turner et al. From fragment to lead: de novo design and development toward a selective FGFR2 inhibitor
Brandvold et al. Exquisitely specific bisubstrate inhibitors of c-Src kinase